CD274 and hepatocellular carcinoma: We also used PDOs from HCC patients with different responses to Atezolizumab (anti‐PD‐L1 Ab), and constructed the MSC‐PDO‐PBMC model to assess the sensitivity of immunotherapy (Figure 6D).